Table 1:
Demographic, clinicopathologic, treatment, and recurrence data
| Characteristic | Uterine carcinosarcoma patients (n=140) |
|---|---|
| Clinical | |
| Median age, years (range) | 67 (36–91) |
| Median BMI, kg/m2 (range) | 30 (17–73) |
| Race | |
| White | 100 (71.4%) |
| Black | 35 (25.0%) |
| Asian | 2 (1.4%) |
| Other or unknown | 3 (2.1%) |
| Prior Treatment History | |
| Prior Pelvic Radiation | 1 (0.7%) |
| Prior Chemotherapy | 7 (5.3%) |
| Prior Tamoxifen Use | 13 (9.3%) |
| Pathology | |
| FIGO Stage | |
| IA | 94 (67.1%) |
| IB | 30 (21.4%) |
| II | 16 (11.4%) |
| Deep myometrial invasion (≥ 50%) (n=126) | 36 (29%) |
| Median tumor size, cm (range) | 6.0 (0.3–21.0) |
| Lymphovascular space invasion present (n=137) | 55 (40.2%) |
| Heterologous component present (n=132) | 57 (43.2%) |
| Majority sarcoma component (≥ 50%) (n = 67) | 35 (52.2%) |
| Rhabdomyosarcoma component present (n=128) | 31 (24.2%) |
| Adjuvant Treatment (n=140) | |
| Summary of adjuvant treatment approach | |
| None | 52 (37.1%) |
| VBT only | 20 (14.3%) |
| Whole pelvic radiation therapy (with or without VBT) | 22 (15.7%) |
| VBT with chemotherapy | 21 (15.0%) |
| Whole pelvic radiation therapy with chemotherapy | 12 (9.3%) |
| Chemotherapy alone | 13 (9.3%) |
| Recurrence (n=137) | |
| Recurrence during follow-up | 70 (51.1%) |
| Treatment for recurrence (n=70) | |
| No treatment | 14 (20.0%) |
| Chemotherapy | 32 (45.7%) |
| Radiation | 10 (14.3%) |
| Chemo and radiation | 5 (7.1%) |
| Surgery alone | 2 (2.8%) |
| Surgery with chemotherapy or radiation | 6 (8.6%) |
| Hormones alone | 1 (1.4%) |
VBT = vaginal brachytherapy